Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 772-798
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Table 3 Risk factors for immune checkpoint inhibitor-mediated colitis and diarrhea
Ref. | Number of patients | ICI targets | Malignancies | GI malignancies | Risk factors for IMC | OR or RR | 95%CI | Fisher's exact P value |
Wolchok et al[49], 2010 | 217 | CTLA-4 | Melanoma | None | High dose ipilimumab | 2.01 | 0.52-7.82 | |
Ascierto et al[50], 2017 | 727 | CTLA-4 | Melanoma | None | High dose ipilimumab | 1.83 | 1.07-0.14 | |
Wang et al[46], 2018 | 327 | CTLA-4 | Melanoma | None | Race (Caucasian) | 5.76 | 2.03-16.36 | |
Combination1 | Solid tumors | Cancer stage IV vs stage III | 0.09 | 0.03-0.30 | ||||
PD-1 | Hematologic | Melanoma | 1.96 | 1.04-3.67 | ||||
PD-L1 | Ipilimumab or combination1 | 2.23 | 1.03-4.81 | |||||
Abu-Sbeih et al[53], 2019 | 346 | CTLA-4 | Melanoma | None | Race (Caucasian) | NA | NA | 0.023 |
Combination1 | Lower mean lactate dehydrogenase | NA | NA | 0.011 | ||||
PD-1 | ||||||||
PD-L1 | ||||||||
Grover et al[40], 2020 | 213 | CTLA-4 | Melanoma | None | Combination1 vs pembrolizumab | 3.34 | 1.1-9.8 | |
Combination1 | CTLA-4 vs PD-1 | 7.14 | 2.2-25.0 | |||||
PD-1 | Neutrophil-to-lymphocyte ratio ≥ 5 | 0.34 | 0.1-0.9 | |||||
Vitamin D intake | 0.35 | 0.1-0.9 | 0.03 | |||||
Pneumococcal pneumonia vaccine | NA | NA | 0.05 | |||||
Influenza or pneumonia vaccine | NA | NA | 0.05 |
- Citation: Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798
- URL: https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.772